Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• TECTONIC CAD and NODULE-SHOCK: IVL in Patients With Severely Calcified Lesions
  Two separate studies presented at TCT 2026 and simultaneously published in JACC: Cardiovascular Interventions address the safety and effectiveness of intravascular lithotripsy (IVL) in patients with severely calcified lesions.
• REMEDY-PILOT: Coronary Sinus Reducer Shows No Significant Improvement in Patients With CMD and ANOCA
  In patients with coronary microvascular dysfunction (CMD) and refractory angina with nonobstructive coronary arteries (ANOCA), coronary sinus reducer (CSR) implantation did not significantly improve myocardial perfusion reserve (MPR), patient-reported symptoms or quality of life, according to results from REMEDY-PILOT trial, presented at TCT 2026.
• HD-PCI: Higher Dose Heparin Does Not Show Appreciable Benefit Over Lower Dose During PCI
  Higher-dose unfractionated heparin (UFH) during PCI did not improve clinical outcomes vs. a lower-dose strategy, according to findings from the HD-PCI trial presented at TCT 2026.
• P4 and TRANSFORM II: CCTA-Guided vs. IVUS-Guided PCI; Sirolimus-Coated Balloon vs. Drug-Eluting Stents
  A PCI strategy guided by coronary computed tomographic angiography (CCTA) was noninferior to intravascular ultrasound (IVUS)-guided PCI for target-vessel failure at 12 months, based on findings from the P4 trial presented at TCT 2026 and simultaneously published in NEJM.
• ANDES, PREMIUM Trials Test Different Antithrombotic Strategies After LAAC, Primary PCI
  Two randomized trials published in JACC and presented as Featured Clinical Research at TCT 2026 examine whether scaling back antithrombotic therapy, using short-term anticoagulation rather than dual antiplatelet therapy (DAPT) after left atrial appendage closure (LAAC) and omitting aspirin during primary STEMI in high-risk patients, can limit bleeding while maintaining protection against thrombotic events.